Doctors in Perth are the first researchers to activate, enrol and deliver patient treatment in a multinational, multicentre Phase 3 nuclear medicine trial known as ProstACT GLOBAL, a study targeting advanced prostate cancer.
ProstACT GLOBAL is sponsored byTelix Pharmaceuticals.
The trial is researching the use of a new form of radiopharmaceutical – a radio antibody-drug conjugate (rADC) – in combination with the existing standard of care.
The trial drug is attracted to a protein called prostate-specific membrane antigen (PSMA), found on the surface of prostate cancer cells. Once deployed in the body, it aims to selectively target tumour cells with radiation therapy and avoid healthy areas.
GenesisCare’s clinical head of theranostics and nuclear medicine, Dr Aviral Singh, is a principal investigator on the trial at the oncology care provider’s Theranostics facility at St John of God Murdoch Hospital in Murdoch Western Australia.
“We are pleased to be the first location to advance this international trial and demonstrate GenesisCare’s commitment to searching for more ways to treat advanced prostate cancer in an exciting and emerging area of medicine," said Dr Singh.
“Our aim is to support our patients while contributing to the growing body of research in the field of Theranostics and use of radiopharmaceuticals around the world. Clinical studies are crucial in understanding more about theranostics as a safe, targeted, and individualised treatment option,” said Dr Singh.
"The trial will study the efficacy in terms of overall and progression-free survival, safety in terms of possible adverse effects, and quality of life following treatment with this rADC agent and provide new information about its uptake within the tumours and organs through an evaluation of pharmacokinetics, biodistribution and radiation dosimetry,” said Dr Singh.
The study is a multinational, multicentre, prospective, randomised, controlled, open-label Phase 3 study targeting advanced progressive metastatic prostate cancer, which has not responded to other forms of treatment and has spread through the body.
The trial builds on previous Phase 1 and Phase 2 studies investigating the safety of this rADC and how it may improve overall survival and quality of life for prostate cancer patients.